|
16 Sep 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1310.40 |
1287.37 |
- |
-1.76 |
hold
|
|
|
|
|
29 Oct 2022
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1310.40
|
|
4433.70
(-70.44%)
|
Pre-Bonus/ Split |
Hold
|
|
|
Q2 revenue up 9% YoY on sales of gRevlimid in the US; gross margin expansion aids EBITDA growth of 42% YoY
|
|
29 Oct 2022
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1310.40
|
5180.00
|
4433.70
(-70.44%)
|
Target met |
Buy
|
|
|
|
|
01 Aug 2022
|
Dr. Reddy's Labs
|
SMC online
|
1310.40
|
|
4096.30
(-68.01%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
29 Jul 2022
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1310.40
|
4750.00
|
4110.45
(-68.12%)
|
Target met |
Buy
|
|
|
|
|
29 Jul 2022
|
Dr. Reddy's Labs
|
ICICI Direct
|
1310.40
|
4750.00
|
4090.35
(-67.96%)
|
Target met |
Buy
|
|
|
|
|
29 Jun 2022
|
Dr. Reddy's Labs
|
Axis Direct
|
1310.40
|
4750.00
|
4364.35
(-69.97%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 4,750.
|
|
24 Jun 2022
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1310.40
|
4925.00
|
4294.90
(-69.49%)
|
Target met |
Buy
|
|
|
DRL has devised a two-pronged strategy to drive long-term growth, classified as Horizon 1 and Horizon 2. Horizon 1 – Growing the core, short-medium term drivers of growth. ? Horizon 2 Building the future, short-long term drivers of growth
|
|
23 Jun 2022
|
Dr. Reddy's Labs
|
Geojit BNP Paribas
|
1310.40
|
5026.00
|
4309.65
(-69.59%)
|
Pre-Bonus/ Split |
Buy
|
|
|
|
|
22 Jun 2022
|
Dr. Reddy's Labs
|
ICICI Direct
|
1310.40
|
4960.00
|
4260.90
(-69.25%)
|
Target met |
Buy
|
|
|
|
|
22 Jun 2022
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1310.40
|
4900.00
|
4294.90
(-69.49%)
|
Target met |
Buy
|
|
|
|